News Kyowa Kirin Co., Ltd. OTC Markets

Equities

KYKOY

US50156R1077

Delayed OTC Markets Other stock markets 09:50:18 2024-07-16 am EDT			5-day change	1st Jan Change
19.85 ^USD	+0.27%		0.00%	+22.18%

Jul. 03	Kyowa Kirin Buys Back Shares	MT
Jul. 02	Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kyowa Kirin Buys Back Shares	Jul. 03	MT
Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	Jul. 02	CI
Kyowa Kirin : Announces Application for Additional Formulation of “LUMICEF® Subcutaneous Injection 210 mg Pen” in Japan	Jun. 28	PU
Ex-dividend day for interim dividend	Jun. 26	FA
Kyowa Kirin Repurchases 3.3 Million Shares in May	Jun. 05	MT
Kyowa Kirin : Announces Approval for Partial Change of Approved Indication of G-Lasta® for the Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Blood Stem Cell Transplantation in Japan (243KB)	May. 17	PU
Kyowa Kirin : Transcript of Results Briefing Fiscal 2024 First Quarter (0B)	May. 09	PU
Kyowa Kirin's Profit Up 15% in Q1	May. 07	MT
Kyowa Kirin : Results Presentation Fiscal 2024 First Quarter (0B)	May. 07	PU
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List	May. 06	AQ
Kyowa Kirin Buys Back Shares for 5.6 Billion Yen in April	May. 06	MT
BridgeBio Pharma Shares Decline After Q1 Financial Results	May. 02	MT
Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ (istradefylline) and Other Parkinson's Disease Add-On Therapies	Apr. 15	AQ
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome	Apr. 15	BU
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	Apr. 08	RE
Kyowa Kirin Buys Back 4 Billion Yen Worth of Shares in March	Apr. 03	MT
Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	Apr. 02	CI
Japanese Shares Slip into Red Amid Profit-Taking; Tokyo Inflation Eyed	Mar. 25	MT
Kyowa Kirin to Allocate Over 84,000 Treasury Shares as Director, Officer Compensation	Mar. 25	MT
Kyowa Kirin's gene therapy most expensive US drug with $4.3 million price tag	Mar. 20	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kyowa Kirin Co., Ltd. OTC Markets

Equities

KYKOY

US50156R1077

Summary

Filters